Abortion Pills, FDA Approval, and Legal Battle: What’s at Stake in the Latest Reproductive Rights Fight

While litigation is pending challenging the regulatory clearance of abortion medications, the Biden administration has asked the Supreme Court to intervene to make them available. This move is in response to a recent judgement from the Fifth Circuit that maintained temporary restrictions on mifepristone pills.

U.S. Attorney General Merrick Garland was very unhappy with the appeals court’s ruling, which reversed a ruling from more than two decades earlier by a federal judge in Texas that had overturned the FDA’s approval of mifepristone, a medication used in more than half of all abortions in the United States. A judge in Texas has issued an injunction blocking the use of mifepristone, which goes into force on Friday.

Noting that the statute of limitations could be an impediment to the plaintiffs’ claim, the Fifth Circuit allowed the Biden administration’s emergency move to stay the Texas judgement until a complete appeal could be heard. A section of the Texas court’s ruling limiting access to mifepristone via postal prescription and requiring that only licensed physicians supply prescriptions was upheld by the appeals court.

Keep Reading

Experts say this judgement is one of the most important on reproductive rights since Roe v. Wade was handed down by the Supreme Court last year. The ruling is the result of a complaint filed in November by an anti-abortion group alleging that the FDA illegally allowed the use of mifepristone to terminate pregnancies, especially among teenage girls.

The Food and Drug Administration, along with other healthcare groups and the pharmaceutical industry, have voiced strong opposition to the Texas verdict, arguing that mifepristone is a safe and effective abortion medication. More than 400 pharmaceutical company CEOs signed an open letter expressing concern that the ruling could undermine government authority and affect the whole industry.

The FDA’s scientific judgment is at stake, and the Biden administration wants to ensure that all Americans have continued access to safe and effective reproductive care. Potentially far-reaching consequences for reproductive rights and healthcare access in the United States hinge on the outcome of the legal struggle over the regulatory licensing of mifepristone.

Noto

Jakarta-based Newswriter for The Asian Affairs. A budding newswriter that always keep track of the latest trends and news that are happening in my country Indonesia.

Recent Posts

Indonesia Extends Sales Ban to Google Pixel Following Non-Compliance with Investment Requirements

Indonesia’s Ministry of Industry has implemented a ban on the sale of Google Pixel phones within the country, adding to…

November 4, 2024

One Piece Unveils Revamped Fish-Man Island Saga with New Opening Theme as Anime Prepares for 2025 Return

One Piece offers a new take of the legendary Fish-Man Island arc, so fans are in for a nostalgic trip…

November 4, 2024

Johor to Pioneer Premium Salaries for Skilled Workers as Malaysia’s First State Initiative under Johor-Singapore SEZ

Particularly in areas related to the forthcoming Johor-Singapore Special Economic Zone (JS-SEZ), Johor is poised to become the first state…

November 4, 2024

China-Japan Diplomatic Groundwork Laid Ahead of Anticipated Xi-Ishiba Summit in South America

China and Japan are getting ready for what would be a historic meeting between Chinese President Xi Jinping and freshly…

November 4, 2024

Philippines Triumphs with Fifth Consecutive East Asia Baseball Cup Title

Celebrating their fifth straight East Asia Baseball Cup title, the Philippines men's baseball team savored a historic triumph. Sunday in…

November 4, 2024

Japan’s Bold “Conveyor Belt Road” to Solve Truck Driver Shortages with Automated Cargo Transport

Officially known as an "auto flow road," the government of Japan has presented plans for a revolutionary "conveyor belt road,"…

November 3, 2024

This website uses cookies.

Read More